AstraZeneca PLC (AZN)vsVenus Concept Inc (VERO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
VERO
Venus Concept Inc
$0.31
0.00%
HEALTHCARE · Cap: $578,190
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 99667% more annual revenue ($58.74B vs $58.88M). AZN leads profitability with a 17.4% profit margin vs -92.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
VERO
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for VERO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -795.0% — below average capital efficiency
Revenue declined 8.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : VERO
The strongest argument for VERO centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : VERO
The primary concerns for VERO are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 12.22 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a value stock while VERO is a turnaround play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Venus Concept Inc
HEALTHCARE · MEDICAL DEVICES · USA
Venus Concept Inc., a medical technology company, develops, markets and offers minimally invasive and non-invasive medical aesthetic and hair restoration technologies globally. The company is headquartered in Toronto, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?